Antibodies to SARS-CoV-2 are associated with protection against reinfection
Lumley SF., O’Donnell D., Stoesser NE., Matthews PC., Howarth A., Hatch SB., Marsden BD., Cox S., James T., Warren F., Peck LJ., Ritter TG., de Toledo Z., Warren L., Axten D., Cornall RJ., Jones EY., Stuart DI., Screaton G., Ebner D., Hoosdally S., Chand M., Crook DW., O’Donnell A-M., Conlon CP., Pouwels KB., Walker AS., Peto TEA., Hopkins S., Walker TM., Jeffery K., Eyre DW.
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>It is critical to understand whether infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent reinfection.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We investigated the incidence of SARS-CoV-2 PCR-positive results in seropositive and seronegative healthcare workers (HCWs) attending asymptomatic and symptomatic staff testing at Oxford University Hospitals, UK. Baseline antibody status was determined using anti-spike and/or anti-nucleocapsid IgG assays and staff followed for up to 30 weeks. We used Poisson regression to estimate the relative incidence of PCR-positive results and new symptomatic infection by antibody status, accounting for age, gender and changes in incidence over time.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 12219 HCWs participated and had anti-spike IgG measured, 11052 were followed up after negative and 1246 after positive antibody results including 79 who seroconverted during follow up. 89 PCR-confirmed symptomatic infections occurred in seronegative individuals (0.46 cases per 10,000 days at risk) and no symptomatic infections in those with anti-spike antibodies. Additionally, 76 (0.40/10,000 days at risk) anti-spike IgG seronegative individuals had PCR-positive tests in asymptomatic screening, compared to 3 (0.21/10,000 days at risk) seropositive individuals. Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]). Rate ratios were similar using anti-nucleocapsid IgG alone or combined with anti-spike IgG to determine baseline status.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Prior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection. Further work is required to determine the long-term duration and correlates of post-infection immunity.</jats:p></jats:sec>